AGEN Agenus, Inc: רווח נקי למניה ב-12 החודשים האחרונים

The daily price action for Agenus (AGEN), whose profit stands at 135.50, is based on payments from licensing agreements. The business relies on botensilimab's exceptional ability to combat resistant neoplasms, which guarantees steady demand. High barriers to entry in the sector are driven by colossal research and development costs and an extensive portfolio of registered patents.

Agenus develops immuno-oncology drugs, for which demand remains stable regardless of economic cycles. This indicator measures the rolling annual dynamics of net profit per share, allowing for an assessment of the business's capitalization efficiency. By analyzing the historical EPS YoY growth over the last 12 months, an investor identifies the real pace of profit growth. The stability of this metric confirms the resilience of the clinical portfolio to macro shocks.